Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Teens are being prescribed Ozempic more than ever before — and some doctors are worried about what the trend could mean.

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Medicamento e demais fármacos liberados integram nova diretriz para tratamento da doença no Brasil; avaliação médica continua ...

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

Valores reduzidos passam a valer nesta segunda-feira, 2, em plataformas de e-commerce e lojas físicas de grandes redes de ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

It's been a tough year for Novo Nordisk, the Danish pharmaceutical company behind the GLP-1 drugs Ozempic and Wegovy. Competitors are nipping at its heels, cheaper knockoffs have been eating into ...

In recent months, a staggering number of women, particularly on social media, have been sharing their experiences with Ozempic, a drug that was originally developed to treat type 2 diabetes.

PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of ...